Moderna Falls on U.S. Patent Proposal, Covid Vaccine Sales Miss
(Bloomberg) -- Moderna Inc. dropped the most in two months in early New York trading Thursday after U.S. President Joe Biden's administration backed waiving patents on Covid-19 vaccines and the company's quarterly revenues missed analysts' expectations.
U.S. support for the patent proposal, intended to increase the supply of life-saving shots, hit vaccine makers, even as Moderna recorded its first-ever profitable quarter and slightly raised annual product sales projections. Novavax Inc., Curevac NV and vaccine partners Pfizer Inc. and BioNTech SE also fell, while Moderna's shares lost 12% as of 9:36 a.m., the most intraday since Feb. 23.
Moderna is racing to bolster production capacity to help inoculate the world from Covid-19, pledging investments in U.S. plants and overseas contractors that will raise supply of its Covid vaccine to as many as 3 billion doses next year. Yet as many countries struggling with a resurgence of the virus, the Biden administration said it will push for a waiver of the rights at the World Trade Organization, and the European Union said it was willing to participate.
A possible patent waiver “doesn't change anything for Moderna,” Chief Executive Officer Stephane Bancel said on a conference call with investors, as there is no excess manufacturing capacity for the vaccine's key ingredient, messenger RNA, anywhere in the world. “We saw the news last night and I didn't lose a minute of sleep.”
Moderna's revenues of $1.94 billion came in short of Wall Street expectations. Its 4.3% increase in projected annual product sales to $19.2 billion pales in comparison to the $26 billion that rival Pfizer Inc. now expects from Covid vaccine sales this year.
The results show just how high the expectations have become for Moderna as it races to keep pace with the Pfizer-BioNTech SE juggernaut to produce vaccines to sell outside the U.S., the country where most of Moderna's initial Covid vaccine supply has gone.
Vaccine in Teens
Meanwhile, Moderna said that initial results from its trial of its Covid vaccine in adolescents ages 12-to-17 showed that it was 96% effective, with no serious safety problems identified so far. The company is continuing to collect data and is in discussions with regulators about amending its emergency use authorization to include teenagers, it said.
On Wednesday, Moderna also released results of preliminary human trials showing that two types of booster shots helped bolster immune responses against variants that surfaced in South Africa and Brazil.
Earnings for the quarter were $2.84 a share, Moderna said. Analysts had expected adjusted earnings of $2.34 a share.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.